Publication | Closed Access
Rituximab exhibits a better safety profile when used as a first line of treatment for pemphigus vulgaris: A retrospective study
40
Citations
17
References
2021
Year
First LineBetter Safety ProfileDermatologyPemphigus VulgarisDrug Resistance
| Year | Citations | |
|---|---|---|
Page 1
Page 1